+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Birch Pollen Allergy R&D Pipeline Analysis Report, Q4 2020

  • ID: 5178677
  • Report
  • October 2020
  • Region: Global
  • 41 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Laboratorios Leti SL
  • Polyrizon Ltd
  • Roxall Medizin GmbH
  • MORE
Birch Pollen Allergy Pipeline Overview

The Q4 Birch Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Birch Pollen Allergy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Birch Pollen Allergy Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Birch Pollen Allergy disease overview, Birch Pollen Allergy types, Birch Pollen Allergy symptoms, causes, and FDA/EMA approved treatment options.

Birch Pollen Allergy Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Birch Pollen Allergy indication. The report presents near-term and long-term pipeline development trends and potential insights.

Birch Pollen Allergy Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies. Business profiles and contact details of the companies actively perusing Birch Pollen Allergy pipeline are assessed.

Birch Pollen Allergy R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Birch Pollen Allergy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Birch Pollen Allergy companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Birch Pollen Allergy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Birch Pollen Allergy Pipeline Market News and Developments during 2020

The Birch Pollen Allergy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Birch Pollen Allergy Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage
  • Birch Pollen Allergy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
  • Company-company partnerships, company-institute partnerships, and investment details of companies are included
  • 8 companies are included including Anergis SA, Biomay AG, HAL Allergy BV, Laboratorios Leti SL, Polyrizon Ltd, Regeneron Pharmaceuticals Inc, Roxall Medizin GmbH, S-TARget therapeutics,
  • Disease overview, Pipeline trends, market analysis, and other developments
  • Potential licensing/new business opportunities in Birch Pollen Allergy pipeline market
Highlights
  • Global coverage of companies and pipeline agents
  • 2020 Trends, market analysis, and developments
  • Potential growth opportunities
  • Comprehensive details of drug candidates
Reasons to Buy
  • Drive pipeline research and commercial assessment
  • Assess most promising drug candidates and stay ahead of the competition
  • Strengthen your pipeline through identifying business expansion and acquisition opportunities
  • Develop new candidates based on most focused targets and mechanism of actions
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Laboratorios Leti SL
  • Polyrizon Ltd
  • Roxall Medizin GmbH
  • MORE
1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Birch Pollen Allergy Pipeline Trends and Insights
2.1 Dominant Phase type of Birch Pollen Allergy Pipeline, 2020
2.2 Most focused Mechanism of Action in Birch Pollen Allergy Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Birch Pollen Allergy pipeline
2.5 Active Companies Developing Birch Pollen Allergy pipeline

3. Birch Pollen Allergy Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options

4. Birch Pollen Allergy Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Laboratorios Leti SL
  • Polyrizon Ltd
  • Regeneron Pharmaceuticals Inc
  • Roxall Medizin GmbH
  • S-TARget therapeutics
5. Birch Pollen Allergy Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details

6. Birch Pollen Allergy Pipeline Market News and Developments during 2020

7. Appendix
7.1 About the Publisher
7.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Laboratorios Leti SL
  • Polyrizon Ltd
  • Regeneron Pharmaceuticals Inc
  • Roxall Medizin GmbH
  • S-TARget therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll